Fredric Schiffer

Dr. Fredric Schiffer

Harvard Medical School
+2
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Behavioral and Brain Functions
Verified
Journal Article
Open access
PDF file
FSFredric Schiffer
Fredric Schiffer
AJAndrea L Johnston
Andrea L Johnston
CRCaitlin Ravichandran
Caitlin Ravichandran
APAnn Polcari
Ann Polcari
MTMartin H Teicher
Martin H Teicher
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin
Many studies have reported beneficial effects from the application of near-infrared (NIR) light photobiomodulation (PBM) to the body, and one group has reported beneficial effects applying it to the brain in stroke patients. We have reported that the measurement of a patient's left and right hemispheric emotional valence (HEV) may clarify data and guide lateralized treatments. We sought to test whether a NIR treatment could 1. improve the psychological status of patients, 2. show a relationship between immediate psychological improvements when HEV was taken into account, and 3. show an increase in frontal pole regional cerebral blood flow (rCBF), and 4. be applied without side effects.

1 January 2007 in Behavioral and Brain Functions
Verified
Journal Article
Open access
PDF file
FSFredric Schiffer
Fredric Schiffer
MTMartin H Teicher
Martin H Teicher
CACarl Anderson
Carl Anderson
ATAkemi Tomoda
Akemi Tomoda
APAnn Polcari
Ann Polcari
SASusan Andersen
Susan Andersen
Much has been theorized about the emotional properties of the hemispheres. Our review of the dominant hypotheses put forth by Schore, Joseph, Davidson, and Harmon-Jones on hemispheric emotional valences (HEV) shows that none are supported by robust data. Instead, we propose that individual's hemispheres are organized to have differing HEVs that can be lateralized in either direction.

1 April 2019 in Medical Hypotheses
Verified
Journal Article
Open access
FSFredric Schiffer
Fredric Schiffer
Penrose and Hameroff assert that brain computations, including quantum computations, involving hydrophobic areas of microtubules whose electron clouds go into orchestrated superpositions and reductions that lead to proto-conscious elements, or "bings" that become orchestrated into conscious experiences. Their assertion, however, like the findings of the neural correlates of consciousness, does not explain subjectivity, but rather describes necessary conditions for it. Many scientists, including Panksepp, Demasio, and Tononi, have each made great contributions to the field, but none explains how material biological processes acquire subjectivity. Yet, the fact is that subjectivity exists and is and of great importance to evolution. Penrose argues that understanding, which involves subjectivity, must be brought into physics, perhaps an undiscovered aspect. Subjectivity is always of or about certain living brain information even though most brain functions do not have subjectivity. Many quantum fields are known to exist and follow Dyson's definition: "a kind of tension or stress which can exist in empty space in the absence of matter. It reveals itself by producing forces, which act on any material objects that happen to lie in the space the field occupies." My hypothesis is that there may be undiscovered quantum fields, which unlike known fields, induce subjectivity when they interact with certain brain information. They emit quantum particles that exert force and cause changes to material objects (brain patterns conveying information) with which they interact. Information that transports meaning to living material exerts force through the understanding it conveys. There is a continuous interplay between experience and brain information. Experiences profoundly inform the brain and alter brain structure, function, and behavior, and local and integrated brain functions process information and initiate multiple associated experiences. Most experience is non-conscious, as discussed by Wright and others, like the soundtrack of a movie to which our brains respond continuously and emotionally even though, we are only intermittently consciously aware of it. I will explore how non-conscious experience may relate to the self, and how it might become conscious. I will offer present support and directions for testing this plausible hypothesis, as well as potential clinical applications in psychology.

19 August 2020 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
FSFredric Schiffer
Fredric Schiffer
WRWilliam Reichmann
William Reichmann
EFEdward Flynn
Edward Flynn
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin
HMHannah McCormack
Hannah McCormack
Background: Opioid use disorders (OUDs) are an epidemic causing catastrophic consequences to individuals, families, and society despite treatments including psychotherapy, substitution therapy or receptor blockers, and psychoeducation. We have developed a novel treatment that combines unilateral transcranial photobiomodulation (t-PBM) to the hemisphere with a more positive valence by Dual Brain Psychology (DBP). Methods: We used a randomized, double blind, placebo-controlled protocol in which 22 patients with significant opioid cravings and a history of recent or current OUD attended three 1-h weekly sessions. After baseline measures of opioid craving and other psychometrics, subjects received two unilateral t-PBM applications (810 nm CW LED, 250 mW/cm2, 60 J/cm2, 4 min) or a sham (foil-covered LED) at F3 or F4. Prior to any treatment we used two tests to determine which hemisphere was more associated with a negative outlook and cravings and treated that side before the more positive hemisphere. Primary outcome measure was an opioid craving scale (OCS). Secondary outcomes were weekly Hamilton Depression (HDRS) and Anxiety (HARS) Rating Scales prior to treatments and at follow-up. Results: Immediately after treatment the OCS improved significantly for both the sham and active treatments, but one week later the active treatment showed a 51.0% (SD 33.7) decrease in OCS while a week after the sham treatments there was a decrease of only 15.8% (SD 35.0) (by Wilcoxon Sign Rank Test, p = 0.004) and by a mixed model it was p = 0.0071. The effect size for the differences between active and sham was 0.73. For the active treatment from before and after treatment the effect size was 1.51 and for the sham, 0.45. The HDRS improved from a baseline of 15.1 to 8.8 (SD 10.3) a week after the active treatment and to 13.3 (SD 12.9) after the sham (p = 0.0071). HARS improved from 14.7 to 8.0 (SD 13.2) after the active treatments and to 14.3 (SD 16.0) after the sham, p = 0.08. Active treatment of the positive hemisphere after the negative hemisphere significantly improved the OCS, but there was no significant difference after the sham treatment. One patient complained of 2 h of abdominal bloating and dropped out; no other adverse effects were observed. Discussion: Unilateral t-PBM to the hemisphere with a more positive hemispheric emotional valence was an effective and safe treatment for opioid cravings as well as for depression and anxiety. Our results also lend support to the underlying premises of DBP.

1 January 2021 in Journal of Psychiatric Research
Verified
Journal Article
Open access
FSFredric Schiffer
Fredric Schiffer
Opioid Use Disorders (OUD) cause great disfunction and pain to individuals, families, and societies. There are few good treatments. This paper presents a novel, easily applied, painless, therapy that can be applied as an adjunct to psychotherapies and medications. The author presents a retrospective overview and 4 brief case reports. Two are typical of very positively responsive patients, one is of a positively but not remarkably responsive patient, and one of a non-responsive patient. The author used unilateral transcranial photobiomodulation (UtPBM), near infrared mode, applied to the hemisphere with the more positive hemispheric emotional valence (HEV) as a treatment to augment the patients' usual treatment. The case reports are from 42 consecutive patients in his practice with OUD where he has given 382 treatments over 18 months, as needed. The author's subjective clinical observations were that of the 42 patients, 26 (62%) consistently had responses to the UtPBM (as described in the case reports) that were easily observable to the patient and the author as strikingly beneficial, 8 (19%) had helpful, but not remarkable responses, and 8 (19%) had no noticeable response. These 3 characterizations will be illustrated with clinical examples. There were no side-effects reported or observed aside from 2 women who experienced anxiety which resolved with psychotherapy. Using UtPBM as an adjunctive treatment to the author's usual in-depth psychotherapy and medication management, he found subjectively that for the majority of his patients, this treatment was a valuable, safe benefit to their treatment for OUD.

10 August 2021 in Frontiers in Psychiatry
Verified
Journal Article
Open access
FSFredric Schiffer
Fredric Schiffer
AKAlaptagin Khan
Alaptagin Khan
EBElizabeth Bolger
Elizabeth Bolger
EFEdward Flynn
Edward Flynn
WSWilliam P. Seltzer
William P. Seltzer
MTMartin H. Teicher
Martin H. Teicher
Background: The opioid epidemic is a global tragedy even with current treatments, and a novel, safe, and effective treatment would be welcomed. We report here our findings from our second randomized controlled trial to evaluate unilateral transcranial photobiomodulation as a treatment for opioid use disorder.Methods: We enrolled 39 participants with active opioid cravings at 2 sites, 19 received the active treatment which consisted of a 4-min twice weekly (every 3 or 4 days) application of a light-emitting diode at 810 nm with an irradiance of 250 mW/cm2 and a fluence of 60 J/cm2 to the forehead over either the left or right dorsolateral prefrontal cortex with a fluence to the brain of 2.1 J/cm2. Twenty participants received a sham treatment with the same device with foil over the bulb. The side of the treatment was based on Dual-Brain Psychology, which posits that one hemisphere is more affected by past maltreatments and is more prone to anxiety and drug cravings that the other hemisphere. We treated the hemisphere with the more positive hemispheric emotional valence (HEV) by 2 tests for HEV.Results: Our primary outcome was changes in pre-treatment opioid craving scale (OCS) minus baseline, and we found using a mixed model that the active group had a highly significant treatment * time benefit over the sham group, p < 0.0001, effect size at the last follow-up of 1.5. The active treatment benefited those not on buprenorphine as well as those not on it. The TimeLine Follow Back measure of opioid use was significantly better in the actively treated group, p = 0.0001, with an effect size of 0.45. We observed no adverse effects.Conclusion: Active unilateral transcranial photobiomodulation to the brain hemisphere with the better HEV was better than sham in the reduction of opioid cravings and opioid use to a very significant degree in a RCT of 39 participants at 2 independent sites. In the active group those on buprenorphine and those not on it both had improvements in cravings over the study. No adverse responses were reported in either group. ClinicalTrials.gov Identifier: NCT04340622.